ATE542831T1 - Neue antigene und antikörper, die mit adenokarzinomen des pankreasgangs assoziiert sind - Google Patents

Neue antigene und antikörper, die mit adenokarzinomen des pankreasgangs assoziiert sind

Info

Publication number
ATE542831T1
ATE542831T1 AT07820692T AT07820692T ATE542831T1 AT E542831 T1 ATE542831 T1 AT E542831T1 AT 07820692 T AT07820692 T AT 07820692T AT 07820692 T AT07820692 T AT 07820692T AT E542831 T1 ATE542831 T1 AT E542831T1
Authority
AT
Austria
Prior art keywords
antibodies
pda
adenocarcinoma
pancreatic duct
identified
Prior art date
Application number
AT07820692T
Other languages
German (de)
English (en)
Inventor
Francesco Novelli
Barbara Tomaino
Paola Cappello
Original Assignee
Ribovax Biotechnologies Sa
Bioline Diagnostici Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribovax Biotechnologies Sa, Bioline Diagnostici Srl filed Critical Ribovax Biotechnologies Sa
Application granted granted Critical
Publication of ATE542831T1 publication Critical patent/ATE542831T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G01N33/57525—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
AT07820692T 2006-09-29 2007-09-28 Neue antigene und antikörper, die mit adenokarzinomen des pankreasgangs assoziiert sind ATE542831T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06121552 2006-09-29
EP06126726 2006-12-20
PCT/EP2007/060305 WO2008037792A1 (en) 2006-09-29 2007-09-28 Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma

Publications (1)

Publication Number Publication Date
ATE542831T1 true ATE542831T1 (de) 2012-02-15

Family

ID=38895810

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07820692T ATE542831T1 (de) 2006-09-29 2007-09-28 Neue antigene und antikörper, die mit adenokarzinomen des pankreasgangs assoziiert sind

Country Status (18)

Country Link
US (1) US8071721B2 (enExample)
EP (1) EP2069395B1 (enExample)
JP (1) JP2010505104A (enExample)
KR (1) KR20090094227A (enExample)
CN (1) CN101578295B (enExample)
AT (1) ATE542831T1 (enExample)
AU (1) AU2007301966B2 (enExample)
BR (1) BRPI0717282A2 (enExample)
CA (1) CA2664841A1 (enExample)
DK (1) DK2069395T3 (enExample)
EA (1) EA016731B1 (enExample)
ES (1) ES2381304T3 (enExample)
IL (2) IL197868A (enExample)
NO (1) NO20091662L (enExample)
NZ (1) NZ576409A (enExample)
PL (1) PL2069395T3 (enExample)
PT (1) PT2069395E (enExample)
WO (1) WO2008037792A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009137832A2 (en) * 2008-05-09 2009-11-12 Duke University Autoantibodies in the detection and treatment of cancer
IT1398782B1 (it) * 2009-09-11 2013-03-18 Novelli Peptide monofosforilato isolato derivato dall'alfa-enolasi umana utile per la diagnosi e il trattamento dell'adenocarcinoma pancreatico, anticorpi diretti contro il suddetto peptide monofosforilato e loro usi.
ITTO20120523A1 (it) * 2012-06-15 2013-12-16 Natimab Therapeutics S R L Procedimento e kit per la diagnosi in vitro dell'adenocarcinoma duttale pancreatico o per determinare la predisposizione all'adenocarcinoma duttale pancreatico
EP3083697B1 (en) * 2013-12-20 2019-04-17 Development Center for Biotechnology Alpha-enolase specific antibodies and methods of uses in cancer therapy
WO2015106296A1 (en) 2014-01-13 2015-07-16 Berg Llc Enolse 1 (eno1) compositions and uses thereof
CN115786317A (zh) * 2022-12-12 2023-03-14 江苏三联生物工程股份有限公司 重组神经元特异性烯醇化酶及其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753446A (en) * 1993-04-15 1998-05-19 National Jewish Center For Immunology & Respiratory Medicine Mitogen ERK kinase kinase (MEKK) assay

Also Published As

Publication number Publication date
AU2007301966B2 (en) 2013-02-21
ES2381304T3 (es) 2012-05-25
AU2007301966A1 (en) 2008-04-03
KR20090094227A (ko) 2009-09-04
WO2008037792A1 (en) 2008-04-03
IL218442A0 (en) 2012-04-30
IL197868A0 (en) 2011-08-01
EA200970332A1 (ru) 2009-10-30
CA2664841A1 (en) 2008-04-03
PT2069395E (pt) 2012-04-27
US8071721B2 (en) 2011-12-06
NZ576409A (en) 2012-02-24
IL197868A (en) 2013-03-24
JP2010505104A (ja) 2010-02-18
US20100028907A1 (en) 2010-02-04
BRPI0717282A2 (pt) 2013-10-15
EP2069395A1 (en) 2009-06-17
CN101578295B (zh) 2013-02-27
NO20091662L (no) 2009-06-29
PL2069395T3 (pl) 2012-06-29
DK2069395T3 (da) 2012-05-14
EA016731B1 (ru) 2012-07-30
EP2069395B1 (en) 2012-01-25
CN101578295A (zh) 2009-11-11

Similar Documents

Publication Publication Date Title
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
MY150400A (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
MX2008009886A (es) Anticuerpos que enlazan par-2.
MX2010002269A (es) Composiciones y metodos que comprenden proteinas de union para adalimumab.
EP1996716A4 (en) MANIPULATED ANTI-PROSTATE STEAM CELL RESPONSIVES (PSCA) ANTIBODIES FOR CANCER TARGETING
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
CY1118979T1 (el) Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων
MX2009006277A (es) Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
CY1117236T1 (el) Μονοκλωνικα αντισωματα εναντι γλυπικανης-3
BR112012007523A2 (pt) moléculas de anticorpo anti-gcc e composições e métodos relacionados
UA95068C2 (uk) Антиген-зв'язуюча молекула, яка зв'язує еgfr, вектор, що її кодує, та їх застосування
MX2010008570A (es) Anticuerpos alfa5-beta1 y sus usos.
PH12012502193A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
EP4385570A3 (en) Multimeric il-15 soluble fusion molecules and methods of making and using same
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
EA201492253A1 (ru) Конструкторы, связывающиеся с ron, и способы их использования
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
MX2010004910A (es) Anticuerpos monoclonales recombinantes y antigenos correspondientes para canceres colonico y pancreatico.
ATE542831T1 (de) Neue antigene und antikörper, die mit adenokarzinomen des pankreasgangs assoziiert sind
PH12022550056A1 (en) Dll3-targeting antibodies and uses thereof
BRPI0808940A8 (pt) anticorpo humano ou fragmento de ligação do mesmo, antígeno, polinucleotídeo, vetor, célula hospedeira, método para preparar um anticorpo ou um fragmento de ligação ou cadeia(s) de imunoglobulina do mesmo, anticorpo, cadeia de imunoglobulina ou um fragmento de ligação do mesmo, composição, usos do anticorpo ou fragmento de ligação, de um antígeno, de um polinucleotídeo, de um vetor, ou de uma célula, e de uma molécula de ligação a antígeno tumoral, método para clonagem molecular de um anticorpo, e, kit para o diagnóstico de um tumor
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
NO20091181L (no) Anti-C5AR-antistoffer med forbedrede egenskaper
MX2010001237A (es) Nuevos anticuerpos.
ATE504602T1 (de) Für humane matriptase spezifische bindungsproteine